Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: Indications for different disease entities

British Journal of Haematology

Volumn 123, Issue 2, 2003, Pages 253-262

  Rasmussen, Thomas ^a   Theilgaard Mönch, Kim ^a   Hudlebusch, Heidi R ^a   Lodahl, Marianne ^a   Johnsen, Hans E ^a   Dahl, Inger Marie S ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

Global reverse transcription polymerase chain reaction; Immunophenotype; Monoclonal gammopathies of undetermined significance (MGUS); Multiple myeloma; Oncogenesis

Indexed keywords

CD19 ANTIGEN; CD38 ANTIGEN; CD56 ANTIGEN; COMPLEMENTARY DNA; CYCLIN D1; CYCLIN D3; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MYC PROTEIN; TRANSCRIPTION FACTOR;

ARTICLE; CARCINOGENESIS; CELL POPULATION; CELL TRANSFORMATION; COHORT ANALYSIS; CONTROLLED STUDY; DATA ANALYSIS; DISEASE COURSE; FEMALE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC ANALYSIS; GENETIC SCREENING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; ONCOGENE; ONCOGENE C MAF; ONCOGENE C MYC; PLASMA CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 4; CYCLIN D1; DISEASE PROGRESSION; DNA, COMPLEMENTARY; DNA, NEOPLASM; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MULTIPLE MYELOMA; ONCOGENE PROTEINS; ONCOGENES; PARAPROTEINEMIAS; PLASMA CELLS; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSLOCATION, GENETIC;

EID: 0142246510     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04577.x     Document Type: Article

References (29)

1. Avet-Loiseau, H., Facon, T., Daviet, A., Godon, C., Rapp, M.J., Harousseau, J.L., Grosbois, B. & Bataille, R. (1999) 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome. Cancer Research, 59, 4546-4550.
2. Avet-Loiseau, H., Gerson, F., Magrangeas, F., Minvielle, S., Harousseau, J.L. & Bataille, R. (2001) Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood, 98, 3082-3086.
3. Avet-Loiseau, H., Facon, T., Grosbois, B., Magrangeas, F., Rapp, M.J., Harousseau, J.L., Minvielle, S. & Bataille, R. (2002) Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood, 99, 2185-2191.
4. Bergsagel, P.L., Chesi, M., Nardini, E., Brents, L.A., Kirby, S.L. & Kuehl, W.M. (1996) Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proceedings of the National Academy of Sciences of the USA, 93, 13931-13936.
5. Chesi, M., Nardini, E., Brents, L.A., Schrock, E., Ried, T., Kuehl, W.M. & Bergsagel, P.L. (1997) Frequent translocation t(4;14) (p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nature Genetics., 16, 260-264.
6. Dahl, I.M., Rasmussen, T., Kauric, G. & Husebekk, A. (2002) Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma. British Journal of Haematology, 116, 273-277.
7. Fenton, J.A., Pratt, G., Rawstron, A.C., Sibley, K., Rothwell, D., Yates, Z., Dring, A., Richards, S.J., Ashcroft, A.J., Davies, F.E., Owen, R.G., Child, J.A. & Morgan, G.J. (2003) Genomic characterization of the chromosomal breakpoints of t(4;14) of multiple myeloma suggests more than one possible aetiological mechanism. Oncogene, 22, 1103-1113.
8. Fonseca, R., Oken, M.M. & Greipp, P. (2001) The t(4;14) (p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance. Blood, 98, 1271-1272.
9. Fonseca, R., Bailey, R.J., Ahmann, G.J., Rajkumar, S.V., Hoyer, J.D., Lust, J.A., Kyle, R.A., Gertz, M.A., Greipp, P.R. & Dewald, G.W. (2002a) Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood, 100, 1417-1424.
10. Fonseca, R., Blood, E.A., Oken, M.M., Kyle, R.A., Dewald, G.W., Bailey, R.J., Van Wier, S.A., Henderson, K.J., Hoyer, J.D., Harrington, D., Kay, N.E., Van Ness, B. & Greipp, P.R. (2002b) Myeloma and the t(11;14) (q13;q32); evidence for a biologically defined unique subset of patients. Blood, 99, 3735-3741.
11. Hallek, M., Leif, B.P. & Anderson, K.C. (1998) Multiple myeloma: increasing evidence for a multistep transformation process. Blood, 91, 3-21.
12. Hoechtlen-Vollmar, W., Menzel, G., Bartl, R., Lamerz, R., Wick, M. & Seidel, D. (2000) Amplification of cyclin D1 gene in multiple myeloma: clinical and prognostic relevance. British Journal of Haematology, 109, 30-38.
13. Iida, S., Rao, P.H., Butler, M., Corradini, P., Boccadoro, M., Klein, B., Chaganti, R.S. & Dalla-Favera, R. (1997) Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nature Genetics, 17, 226-230.
14. Keats, J.J., Reiman, T., Maxwell, C.A., Taylor, B.J., Larratt, L.M., Mant, M.J., Belch, A.R. & Pilarski, L.M. (2003) In multiple myeloma, t(4;14) (p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood, 101, 1520-1529.
15. Kuehl, W.M. & Bergsagel, P.L. (2002) Multiple myeloma: involving genetic events and host interactions. Nature Reviews of Cancer. 2. 175-187.
16. Kyle, R.A., Therneau, T.M., Rajkumar, S.V., Offord, J.R., Larson, D.R., Plevak, M.F. & Melton, III, L.J. (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. New England Journal of Medicine, 346, 564-569.
17. Malgeri, U., Baldini, L., Perfetti, V., Fabris, S., Vignarelli, M.C., Colombo, G., Lotti, V., Compasso, S., Bogni, S., Lombardi, L., Maiolo, A.T. & Neri, A. (2000) Detection of t(4;14) (p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts. Cancer Research, 60, 4058-4061.
18. Nishida, K., Tamura, A., Nakazawa, N., Ueda, Y., Abe, T., Matsuda, F., Kashima, K. & Taniwaki, M. (1997) The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood, 90, 526-534.
19. Nobuyoshi, M., Kawano, M., Tanaka, H., Ishikawa, H., Tanabe, O., Iwato, K., Asaoku, H., Sakai, A. & Kuramoto, A. (1991) Increased expression of the c-myc gene may be related to the aggressive transformation of human myeloma cells. British Journal of Haematology, 77, 523-528.
20. Pellat-Deceunynck, C., Barille, S., Jego, G., Puthier, D., Robillard, N., Pineau, D., Rapp, M.J., Harousseau, J.L., Amiot, M. & Bataille, R. (1998) The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma, Leukemia, 12, 1977-1982.
21. Rasmussen, T., Jensen, L., Honore, L., Andersen, H. & Johnsen, H.E. (1999) Circulating clonal cells in multiple myeloma do not express CD34 mRNA, as measured by single-cell and real-time RT-PCR assays. British Journal of Haematology, 107, 818-824.
22. Rasmussen, T., Poulsen, T.S., Honore, L. & Johnsen, H.E. (2000) Quantitation of minimal residual disease in multiple myeloma using an allele specific real-time PCR assay. Experimental Hematology, 28, 1039-1045.
23. Rawstron, A., Barrans, S., Blythe, D., Davies, F., English, A., Pratt, G., Child, A., Morgan, G. & Jack, A. (1999) Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression. British Journal of Haematology, 104, 138-143.
24. Sahara, N., Takeshita, A., Shigeno, K., Fujisawa, S., Takeshita, K., Naito, K., Ihara, M., Ono, T., Tamashima, S., Nara, K., Ohnishi, K. & Ohno, R. (2002) Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. British Journal of Haematology, 117, 882-885.
25. Shaughnessy, Jr. J., Gabrea, A., Qi, Y., Brents, L., Zhan, F., Tian, E., Sawyer, J., Barlogie, B., Bergsagel, P.L. & Kuehl, M. (2001) Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood, 98, 217-223.
26. Shou, Y., Martelli, M.L., Gabrea, A., Qi, Y., Brents, L.A., Roschke, A., Dewald, G., Kirsch, I.R., Bergsagel, P.L. & Kuehl, W.M. (2000) Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proceedings of the National Academy of Sciences of the USA, 97, 228-233.
27. Soverini, S., Cavo, M., Terragna, C., Zamagni, E., Ruggeri, D., Cellini, C., Testoni, N., Tosi, P., de Vivo, A., Amabile, M., Grafone, T., Ottaviani, E., Giannini, B., Cangini, D., Bonifazi, F., Neri, A., Fabris, S., Tura, S., Baccarani, M. & Martinelli, G. (2003) Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. Prepublished online May 1. Blood, 102, 1588-1594.
28. Theilgaard-Monch, K., Cowland, J. & Borregaard, N. (2001) Profiling of gene expression in individual hematopoietic cells by global mRNA amplification and slot blot analysis. Journal of Immunological Methods, 252, 175-189.
29. Troussard, X., Avet-Loiseau, H., Marcro, M., Mellerin, M.P., Malet, M., Roussel, M.F. & Sola, B. (2000) Cyclin D1 expression in patients with multiple myeloma. Haematology Journal, 1, 181-185.